(Non-)translational medicine: targeting bacterial RNA

The rise and spread of antibiotic resistance is among the most severe challenges facing modern medicine. Despite this fact, attempts to develop novel classes of antibiotic have been largely unsuccessful. The traditional mechanisms by which antibiotics work are subject to relatively rapid bacterial r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in genetics Jg. 4; S. 230
Hauptverfasser: Dinan, Adam M., Loftus, Brendan J.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland Frontiers Media S.A 2013
Schlagworte:
Genetics
riboswitch
bacteria
locked nucleic acids
non-coding RNA
small RNA
antibiotics
antisense
external guide sequence
ISSN:1664-8021, 1664-8021
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The rise and spread of antibiotic resistance is among the most severe challenges facing modern medicine. Despite this fact, attempts to develop novel classes of antibiotic have been largely unsuccessful. The traditional mechanisms by which antibiotics work are subject to relatively rapid bacterial resistance via mutation, and hence have a limited period of efficacy. One promising strategy to ameliorate this problem is to shift from the use of chemical compounds targeting protein structures and processes to a new era of RNA-based therapeutics. RNA-mediated regulation (riboregulation) has evolved naturally in bacteria and is therefore a highly efficient means by which gene expression can be manipulated. Here, we describe recent advances toward the development of effective anti-bacterial therapies, which operate through various strategies centered on RNA.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: William Cho, Queen Elizabeth Hospital, Hong Kong
This article was submitted to Non-Coding RNA, a section of the journal Frontiers in Genetics.
Reviewed by: Aaron J. Schetter, National Cancer Institute, USA; Bing Yao, Emory University, USA
ISSN:1664-8021
1664-8021
DOI:10.3389/fgene.2013.00230